A phase 2 study of 99mTc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer

Annals of Surgical Oncology

Volumn 18, Issue 4, 2011, Pages 961-969

  Leong, Stanley P L ^a   Kim, Julian ^b   Ross, Merrick ^c   Faries, Mark ^d   Scoggins, Charles R ^e   Metz, Wendy L Rich ^f   Cope, Frederick O ^f   Orahood, Richard C ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d JOHN WAYNE CANCER INSTITUTE   (United States)

^e University of Louisville School of Medicine   (United States)

^f Neoprobe Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TILMANOCEPT TECHNETIUM TC 99M; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE EVALUATION; SENTINEL LYMPH NODE; TISSUE SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DEXTRANS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MANNANS; MELANOMA; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PENTETIC ACID; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; YOUNG ADULT;

EID: 79955807778     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1524-z     Document Type: Article

References (32)

1. Leong SP, Donegan E, Heffernon W, Dean S, Katz JA. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361-6. (Pubitemid 30397478)
2. Komenaka IK, Bauer VP, Schnabel FR, et al. Allergic reactions to isosulfan blue in sentinel lymph node mapping. Breast J. 2005;11:70-2. (Pubitemid 40209349)
3. King TA, Fey JV, Van Zee KJ, et al. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Ann Surg Oncol. 2004;11:535-41. (Pubitemid 40486737)
4. Scherer K, Studer W, Figueiredo V, Bircher AJ. Anaphylaxis to isosulfan blue and cross-reactivity to patent blue v: case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol. 2006;96:497-500.
5. Efron P, Knudsen E, Hirshorn S, Copeland EM. Anaphylactic reaction to isosulfan blue used for sentinel node biopsy: case report and literature review. Breast J. 2002;8:396-99. (Pubitemid 35334660)
6. Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy-a common event. Surgery. 2001;130:439-42. (Pubitemid 32868455)
7. Mariani G, Gipponi M, Moresco L, et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med. 2002;43:811-27. (Pubitemid 34663305)
8. Krynyckyi BR, Kim CK, Goyenechea MR, et al. Clinical breast lymphoscintigraphy: optimal techniques for performing studies, image atlas, and analysis of images. Radiographics. 2004;24: 121-39. (Pubitemid 38134598)
9. Stojadinovic A, Peoples GE, Jurgens JS, et al. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P Trial): a double-blind, randomized controlled trial. Lancet Oncol. 2009;10:849-54.
10. Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: 99mTc-DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951-9. (Pubitemid 32537445)
11. Hoh CK, Wallace AM, Vera DR. Preclinical studies of [(99m)Tc]DTPA- mannosyl-dextran. Nucl Med Biol. 2003;30: 457-64.
12. Ellner SJ, Hoh CK, Vera DR, et al. Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol. 2003;30:805-10. (Pubitemid 38040988)
13. Wallace AM, Hoh CK, Vera DR, et al. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531-8. (Pubitemid 40486916)
14. Wallace AM, Hoh CK, Darrah DD, et al. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007;34:849-53. (Pubitemid 47503821)
15. Wallace AM, Hoh CK, Limmer KK, et al. Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol. Nucl Med Biol. 2009;36:687-92.
16. Wallace AM, Hoh CK, Ellner, SJ, et al. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913-21. (Pubitemid 46175343)
17. Pukelsheim F. The three sigma rule. Am Stat. 1994;48:88-91.
18. Cipra T, Fuchs A, Formánek J, et al. Detection and interpolation of outliers in biosignals. Act Nerv Super (Praha). 1990;32:283-91.
19. Smirnov NV, Dunin-Barkovskii IV. Mathematische Statistik in der Technik. Verlag Wissenschaft; 1969.
20. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymphnode dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-8. (Pubitemid 47488052)
21. Weaver DL, Le UP, Dupuis SL, et al. Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy. Am J Surg Pathol. 2009;33: 1583-9.
22. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17. (Pubitemid 44465459)
23. Méndez J, Wallace AM, Hoh CK, Vera DR. Detection of gastric and colonic sentinel nodes through endoscopic administration of 99mTc-DTPA-mannosyl- dextran in pigs. J Nucl Med. 2003;44: 1677-81. (Pubitemid 39663343)
24. Wallace AM, Ellner SJ, Mendez J, et al. Minimally invasive sentinel lymph node mapping of the pig colon with Lymphoseek. Surgery. 2006;139:217-23. (Pubitemid 43170323)
25. Ellner SJ, Mendez J, Vera DR, et al. Sentinel lymph node mapping of the colon and stomach using Lymphoseek in a pig model. Ann Surg Oncol. 2004;11:674-81. (Pubitemid 40486702)
26. Salem CE, Hoh CK, Wallace AM, Vera DR. A preclinical study of prostate sentinel lymph node mapping with [99mTc]diethylenetriamine pentaacetic acid-mannosyl-dextran. J Urol. 2006; 175:744-8. (Pubitemid 43067442)
27. American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010.
28. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46:765-81.
29. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127: 2893-917.
30. Limmer KK, Povoski SP, Krontiras H, et al. Phase III trial results comparing Lymphoseek with blue dye in detection of the sentinel lymph node in breast cancer (abstract 304). Cancer Res. 2009;69(Suppl 24):514s.
31. Sondak VK, Marzban S, Rich CJ, et al. Identification of melanoma sentinel nodes with Lymphoseek: phase III clinical trial results at Moffitt Cancer Center (abstract P250). Ann Surg Oncol. 2010;17(Suppl 1):S111.
32. Kim J, Ross M, Faries M, et al. A phase 2, single arm, open-label, multicenter study to evaluate the safety and efficacy of Lymphoseek as a lymphoid tissue targeting agent in patients with known or suspected melanoma or breast cancer who are undergoing lymph node mapping (abstract P105). Ann Surg Oncol. 2008;15(Suppl 2):65.